<SEC-DOCUMENT>0001193125-21-003750.txt : 20210107
<SEC-HEADER>0001193125-21-003750.hdr.sgml : 20210107
<ACCEPTANCE-DATETIME>20210107080054
ACCESSION NUMBER:		0001193125-21-003750
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20201231
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210107
DATE AS OF CHANGE:		20210107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36620
		FILM NUMBER:		21513015

	BUSINESS ADDRESS:	
		STREET 1:		19900 MACARTHUR BLVD.
		STREET 2:		SUITE 550
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19900 MACARTHUR BLVD.
		STREET 2:		SUITE 550
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d27027d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:eldn="http://imetrix.edgar-online.com/20201231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2020-12-31_to_2020-12-31">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-12-31_to_2020-12-31">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-12-31_to_2020-12-31">0001404281</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="eldn-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-12-31_to_2020-12-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-31</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-12-31_to_2020-12-31">8-K</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">January 7, 2021 (<ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-12-31_to_2020-12-31" format="ixt:datemonthdayyearen">December 31, 2020</ix:nonNumeric>)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Date of earliest event reported)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2020-12-31_to_2020-12-31">Eledon Pharmaceuticals, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-12-31_to_2020-12-31" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-12-31_to_2020-12-31">001-36620</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-12-31_to_2020-12-31">20-1000967</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-12-31_to_2020-12-31">19900 MacArthur Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2020-12-31_to_2020-12-31">Suite 550</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-12-31_to_2020-12-31">Irvine</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2020-12-31_to_2020-12-31" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-12-31_to_2020-12-31">92612</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including Zip Code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-12-31_to_2020-12-31">(949)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-12-31_to_2020-12-31">238-8090</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-12-31_to_2020-12-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-12-31_to_2020-12-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-12-31_to_2020-12-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-12-31_to_2020-12-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-12-31_to_2020-12-31">Common Stock, $0.001 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-12-31_to_2020-12-31">ELDN</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">Nasdaq Capital Market</span> </span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-12-31_to_2020-12-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold"><span style="text-decoration:underline">Item&#160;3.02</span></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left"><span style="text-decoration:underline">Unregistered Sales of Equity Securities. </span></p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;31, 2020, Eledon Pharmaceuticals, Inc. (the &#8220;Company&#8221;), previously Novus Therapeutics, Inc., entered into an exchange agreement (the &#8220;Series X Exchange Agreement&#8221;) with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P. , MSI BVF SPV, L.L.C. (the &#8220;BVF Exchanging Stockholders&#8221;) and Cormorant Global Healthcare Master Fund, LP (together with the BVF Exchanging Stockholders, the &#8220;Exchanging Stockholders&#8221;), pursuant to which the Exchanging Stockholders exchanged (the &#8220;Series X Exchange&#8221;) 344,666 shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), for 6,203.98 shares of Series X Convertible Preferred Stock (the &#8220;Series X Preferred Stock&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on December&#160;31, 2020 the Company entered into an exchange agreement (the &#8220;Warrant Exchange Agreement,&#8221; and together with the Series X Exchange Agreement, the &#8220;Exchange Agreements&#8221;) with the BVF Exchanging Stockholders, pursuant to which the BVF Exchanging Stockholders exchanged (the &#8220;Warrant Exchange,&#8221; and together with the Series X Exchange, &#8220;the Exchanges&#8221;) 509,117 shares of the Common Stock for one or more <span style="white-space:nowrap">pre-funded</span> warrants to purchase an aggregate of 509,117 shares of the Common Stock at a nominal exercise price (the &#8220;Warrants&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series X Preferred Stock and the Warrants were issued without registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemption from registration contained in Section&#160;3(a)(9) of the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Exchanges, the Company has 14,306,614 shares of Common Stock outstanding and 6,203.98 shares of Series X Preferred Stock outstanding, which are convertible into 344,663 shares of Common Stock (after rounding for fractional shares). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Exchange Agreements are not complete and is qualified in its entirety by references to the full text of the Exchange Agreements, which are filed as an exhibit to this Report and is incorporated by reference herein. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold"><span style="text-decoration:underline">Item&#160;9.01</span></span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left"><span style="text-decoration:underline">Financial Statements and Exhibits. </span></p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:94%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27027dex101.htm">Series X Exchange Agreement, dated December&#160;31, 2020, by and among Novus Therapeutics, Inc. and the Stockholders named therein </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d27027dex102.htm">Warrant Exchange Agreement, dated December&#160;31, 2020, by and among Novus Therapeutics, Inc. and the Stockholders named therein </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Eledon Pharmaceuticals, Inc.</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;7, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David-Alexandre C. Gros</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">David-Alexandre C. Gros</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&#160;</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d27027dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCHANGE AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Exchange Agreement (the &#147;Agreement&#148;), dated as of December&nbsp;31, 2020 (the &#147;Effective Date&#148;), is entered into by and among Novus Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;), and the holders of the
Company&#146;s common stock, par value $0.001 per share (the &#147;Common Stock&#148;) listed on <U>Schedule I</U> attached hereto (each a &#147;Stockholder&#148; and collectively, the &#147;Stockholders&#148; and, together with the Company, the
&#147;Parties&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BACKGROUND</B>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. The Stockholders and the Company wish to exchange an aggregate of 344,666 shares of Common Stock held by the Stockholders for an aggregate
of 6,203.98 newly issued shares (the &#147;Preferred Shares&#148;) of the Company&#146;s Series X Preferred Stock, par value $0.001 per share (the &#147;Preferred Stock&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. The Parties intend the foregoing exchange of the Exchange Shares for the Preferred Shares (the &#147;Exchange&#148;) to be exempt from
registration under the Securities Act of 1933 (the &#147;Act&#148;) pursuant to Section&nbsp;3(a)(9) of Act. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT</B>: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, the Parties hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) <U>Exchange; Closing</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Exchange shall be consummated as of 10:00 a.m. on the third business day following the Effective Date, or at such other
date and time as the Parties may agree (the &#147;Closing Date&#148;). On the Closing Date, and subject to the satisfaction or waiver of the conditions set forth herein, the Stockholders shall exchange the Exchange Shares for the Preferred Shares in
the respective amounts listed on Schedule I attached hereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) On the Closing Date: (i)&nbsp;the Company and the
Stockholders shall jointly and irrevocably instruct the Company&#146;s Registrar and Transfer Agent for the Common Stock to cancel the direct registration book-entry statements from the Transfer Agent evidencing the Exchange Shares, (ii)&nbsp;the
Company shall deliver to the Stockholders a certified copy of the certificate of designations for the Preferred Stock, in the form attached hereto as <U>Exhibit A</U> (the &#147;Certificate of Designations&#148;), as filed with the Secretary of
State of Delaware, and (iii)&nbsp;the Company shall issue the Preferred Shares in book entry, in the amounts and registered in the names set forth on <U>Schedule I</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) <U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Stockholder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither the Company nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing,
has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section&nbsp;3(a)(9) of the Act and the rules and regulations of the SEC promulgated thereunder) for soliciting the
Exchange. Assuming the representations and warranties of the Stockholders contained herein are true and complete, the Exchange will qualify for the registration exemption contained in Section&nbsp;3(a)(9) of the Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has the requisite corporate power and authority and power to enter
into this Agreement and to consummate the Exchange and such transactions shall not contravene any contractual, regulatory, statutory or other obligation or restriction applicable to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It has a sufficient number of authorized and unissued shares of Preferred Stock to consummate the Exchange. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) It has reserved a sufficient number of shares of Common Stock as may be necessary to fully permit the conversion of the
Preferred Stock and the issuance of the underlying Common Stock, without regard to any beneficial ownership limits set forth in the Certificate of Designations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) To the fullest extent applicable, the Exchange, as well as the subsequent conversion of the Preferred Shares into Common
Stock (including the surrender and forfeiture of the Preferred Shares and the issuance of the underlying Common Stock) shall be treated as an exempt transaction under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Securities Exchange
Act of 1934, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) <U>Representations and Warranties of Stockholders</U>. Each Stockholder, as to itself only, represents and
warrants to the Company as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has the requisite power and authority to enter into this Agreement and
consummate the Exchange. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It is the record and beneficial owner of, and has valid and marketable title to, the Exchange
Shares being exchanged by it pursuant to this Agreement, free and clear of any lien, pledge, restriction or other encumbrance (other than restrictions arising pursuant to applicable securities laws), and has the absolute and unrestricted right,
power and capacity to surrender and exchange the Exchange Shares being exchanged by it pursuant to this Agreement, free and clear of any lien, pledge, restriction or other encumbrance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Neither it nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid
or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section&nbsp;3(a)(9) of the Act and the rules and regulations of the SEC promulgated thereunder) for soliciting the Exchange.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) This Agreement, and any action or proceeding arising out of or relating to this Agreement, shall be exclusively governed by
the internal laws of the State of California. Any dispute arising under or relating to this Agreement shall be resolved by binding arbitration, to be conducted in San Francisco, California in accordance with the commercial arbitration rules of the
American Arbitration Association. The prevailing party in such dispute shall be entitled to be awarded fees and expenses, including reasonable attorneys&#146; fees. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This Agreement represents the entire agreement and understanding among the parties regarding the terms and conditions of
the Exchange and supersedes all prior agreements, arrangements and understandings with respect to the subject matter hereof. This Agreement may only be amended in a written instrument executed by the Parties. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which,
when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Upon completion of the Exchange, the Company shall reimburse the
Stockholders for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with effecting the Exchange, including the reasonable fees and disbursements of counsel,
not to exceed $25,000 in total. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each of the Stockholders and the Company acknowledge that Gibson, Dunn&nbsp;&amp;
Crutcher LLP (&#147;Gibson Dunn&#148;) currently represents the Company and one or more Stockholders or their affiliates in unrelated matters. In the course of such representation, Gibson Dunn may have come into possession of confidential
information relating to each party. Each Stockholder and the Company acknowledges that Gibson Dunn is representing only the Company in this transaction and may not share the Company&#146;s confidential information; similarly, Gibson Dunn may not
share any Stockholder&#146;s confidential information with the Company. By executing this Agreement, each Stockholder and the Company hereby waive any actual or potential conflict of interest which has or may arise as a result of Gibson Dunn&#146;s
representation of such persons and entities, and represents that it has had the opportunity to consult with independent counsel concerning the giving of this waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In witness whereof, the Parties have executed this Agreement as of the Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Novus Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jon Kuwahara</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jon Kuwahara</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SVP Finance &amp; Administration</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Biotechnology Value Fund, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Biotechnology Value Fund II, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P. itself GP of Biotechnology Value Fund II, LP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Biotechnology Value Trading Fund OS, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MSI BVF SPV, L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President BVF Inc., General Partner of BVF Partners L.P., itself <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for MSI BVF SPV, L.L.C.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Cormorant Global Healthcare Master Fund, LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bihua Chen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Bihua Chen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Member</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>S<SMALL>CHEDULE</SMALL> I </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Stockholder Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Address</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Common&nbsp;Shares&nbsp;surrendered</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Preferred&nbsp;Shares&nbsp;issued</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">44 Montgomery Street, 40th Floor San Francisco CA, 94104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,211.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund II, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">44 Montgomery Street, 40th Floor San Francisco CA, 94104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,739.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Trading Fund OS, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">44 Montgomery Street, 40th Floor San Francisco CA, 94104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MSI BVF SPV LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">44 Montgomery Street, 40th Floor San Francisco CA, 94104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">200 Clarendon Street, 52nd Floor, Boston, MA 02116</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,782.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>E<SMALL>XHIBIT</SMALL> A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Certificate of Designations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d27027dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g27027g0106224044986.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2020 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novus
Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19900 MacArthur Blvd., Suite 550, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irvine, California, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>3(a)(9) Exchange Agreement</U></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter agreement
(the &#147;<B><I>Agreement</I></B>&#148;) confirms the agreement of Novus Therapeutics, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and the holders of the Common Stock listed on <U>Schedule I</U> attached hereto (the
&#147;<B><I>Stockholders</I></B>&#148;), pursuant to which the Stockholders have agreed to exchange an aggregate of 509,117 shares (the &#147;<B><I>Shares</I></B>&#148;) of Common Stock, par value $0.001 per share (the &#147;<B><I>Common
Stock</I></B>&#148;), beneficially owned by the Stockholders in consideration for one or more Common Stock Warrants in the form attached hereto as Exhibit A (each a &#147;<B><I>Warrant</I></B>&#148;) to purchase an aggregate of 509,117 shares of
Common Stock (the &#147;<B><I>Warrant Shares</I></B>&#148;) on the terms specified below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, the Company
and the Stockholders agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) No later than the close of business on the first business day after the date hereof (the
&#147;<B><I>Closing Date</I></B>&#148;) and subject to the satisfaction or waiver of the conditions set forth herein, the Stockholders shall exchange the Shares for the Warrants (the &#147;<B><I>Exchange</I></B>&#148;) in the respective amounts
listed on <U>Schedule I</U>. The Exchange shall be consummated pursuant to Section&nbsp;3(a)(9) of the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;). On the Closing Date: (a)&nbsp;the Company and the Stockholders
shall jointly and irrevocably instruct Continental Stock Transfer and Trust Company Co. (the &#147;<B><I>Transfer Agent</I></B>&#148;) to cancel the direct registration book-entry statements from the Transfer Agent evidencing the Shares; and
(b)&nbsp;the Company shall irrevocably instruct the Transfer Agent to issue and deliver to the Stockholders the Warrants representing the Warrant Shares, in the amounts and in the names set forth on <U>Schedule I</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) The Company represents and warrants to each Stockholder as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Neither the Company nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing,
has paid or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section&nbsp;3(a)(9) of the Securities Act and the rules and regulations of the Commission promulgated thereunder) for
soliciting the Exchange. Assuming the representations and warranties of the Stockholders contained herein are true and complete, the Exchange will qualify for the registration exemption contained in Section&nbsp;3(a)(9) of the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has the requisite corporate power and authority and power to enter into this Agreement and to consummate the Exchange
and such transactions shall not contravene any contractual, regulatory, statutory or other obligation or restriction applicable to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It has reserved a sufficient number of shares of Common Stock as may be necessary to fully permit the exercise of the
Warrants and the issuance of the Warrant Shares, without regard to any beneficial ownership limits set forth in the Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) Each
Stockholder, as to itself only, represents and warrants to the Company as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has the requisite power and
authority to enter into this Agreement and consummate the Exchange. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It is the record and beneficial owner of, and has valid and marketable
title to, the Shares being exchanged by it pursuant to this Agreement, free and clear of any lien, pledge, restriction or other encumbrance (other than restrictions arising pursuant to applicable securities laws), and has the absolute and
unrestricted right, power and capacity to surrender and exchange the Shares being exchanged by it pursuant to this Agreement, free and clear of any lien, pledge, restriction or other encumbrance. It is not a party to or bound by, and the Shares
being exchanged by it pursuant to this Agreement are not subject to, any agreement, understanding or other arrangement (i)&nbsp;granting any option, warrant or right of first refusal with respect to such Shares to any person, (ii)&nbsp;restricting
its right to surrender and exchange such Shares as contemplated by this Agreement, or (iii)&nbsp;restricting any other of its rights with respect to such Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Neither it nor any of its affiliates nor any person acting on behalf of or for the benefit of any of the forgoing, has paid
or given, or agreed to pay or give, directly or indirectly, any commission or other remuneration (within the meaning of Section&nbsp;3(a)(9) and the rules and regulations of the Commission promulgated thereunder) for soliciting the Exchange. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) This agreement, and any action or proceeding arising out of or relating to this agreement, shall be exclusively governed by the laws of the
State of New York. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) In the event that any part of this agreement is declared by any court or other judicial or administrative body to
be null, void or unenforceable, said provision shall survive to the extent it is not so declared, and all of the other provisions of this agreement shall remain in full force and effect. In such an event, the Stockholders and the Company shall
endeavor in good faith negotiations to modify this agreement so as to affect the original intent of the parties as closely as possible. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(6) This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when taken
together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please sign to acknowledge agreement with the above terms and return to the undersigned.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Biotechnology Value Fund, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Biotechnology Value Fund II, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P. itself GP of Biotechnology Value Fund II, LP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Biotechnology Value Trading Fund OS, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MSI BVF SPV, L.L.C.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Lampert</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Mark Lampert</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President BVF Inc., General Partner of BVF Partners L.P., itself <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> for MSI BVF SPV, L.L.C.</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Warrant Exchange Agreement </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acknowledged and agreed to:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Novus Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jon Kuwahara</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jon Kuwahara</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">SVP Finance &amp; Administration</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Warrant Exchange Agreement </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Common&nbsp;Stock</B><br><B>to be Exchanged</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrant&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Fund II, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biotechnology Value Trading Fund OS, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MSI BVF SPV, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g27027g0106223143874.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject to adjustment)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Original Issue Date: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Novus Therapeutics, Inc. (the &#147;<I>Company</I>&#148;), hereby certifies that, for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, [ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] or its permitted registered assigns (the &#147;<I>Holder</I>&#148;), is entitled, subject to the
terms set forth below, to purchase from the Company up to a total of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] shares of common stock, $0.001 par value per share (the &#147;<I>Common Stock</I>&#148;), of the Company
(each such share, a &#147;<I>Warrant Share</I>&#148; and all such shares, the &#147;<I>Warrant Shares</I>&#148;) at an exercise price per share equal to $0.001 per share (as adjusted from time to time as provided in
<U>Section</U><U></U><U>&nbsp;9</U> herein, the &#147;<I>Exercise Price</I>&#148;), upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the
&#147;<I>Warrant</I>&#148;) at any time and from time to time on or after the date hereof (the &#147;<I>Original Issue Date</I>&#148;) and through and including 5:30 P.M., New York City time, on the date that is 10 years following the Original Issue
Date (the &#147;<I>Expiration Date</I>&#148;), and subject to the following terms and conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Definitions</U>. For purposes of this Warrant, the following terms shall have the following meanings:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<I>Affiliate</I>&#148; means any Person directly or indirectly controlled by, controlling or under common
control with, a Holder, but only for so long as such control shall continue. For purposes of this definition, &#147;control&#148; (including, with correlative meanings, &#147;controlled by,&#148; &#147;controlling&#148; and &#147;under common
control with&#148;) means, with respect to a Person, possession, direct or indirect, of (a)&nbsp;the power to direct or cause direction of the management and policies of such Person (whether through ownership of securities or partnership or other
ownership interests, by contract or otherwise), or (b)&nbsp;at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<I>Commission</I>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<I>Closing Sale Price</I>&#148; means, for any security as of any date, the last trade price for such security on the Principal
Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security
prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets, or, if no last trade price is reported for such
security by Bloomberg Financial Markets, the average of the bid and ask prices, of any market makers for such security as reported in the &#147;pink sheets&#148; by Pink Sheets LLC. If the Closing Sale Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair
market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#146; determination shall be binding upon all parties absent demonstrable error.
All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<I>Principal Trading Market</I>&#148; means the national securities exchange or other trading market on which the Common Stock is
primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be The Nasdaq Global Market. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Securities Act</I>&#148; means the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<I>Trading Day</I>&#148; means any weekday on which the Principal Trading Market is open for trading.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<I>Transfer Agent</I>&#148; means [&#149;]., the Company&#146;s transfer agent and
registrar for the Common Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Registration of Warrants</U>. The Company shall register this Warrant,
upon records to be maintained by the Company for that purpose (the &#147;<I>Warrant Register</I>&#148;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered assignee to which this Warrant
is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Registration of Transfers</U>. Subject to compliance with all applicable securities laws, the
Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such
registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<I>New Warrant</I>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the
transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such
transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any
New Warrant under this <U>Section</U><U></U><U>&nbsp;3</U>. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any
notice to the contrary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Exercise and Duration of Warrants</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by
<U>Section</U><U></U><U>&nbsp;10</U> of this Warrant at any time and from time to time on or after the Original Issue Date and through and including 5:30 P.M. New York City time, on the Expiration Date. At 5:30 P.M., New York City time, on the
Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value and this Warrant shall be terminated and no longer outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company (i)&nbsp;an exercise notice, in the form attached as <U>Schedule 1</U>
hereto (the &#147;<I>Exercise Notice</I>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a &#147;cashless
exercise&#148; if so indicated in the Exercise Notice pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below), and the date on which the last of such items is delivered to the Company (as determined in accordance with the notice provisions hereof)
is an &#147;<I>Exercise Date</I>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the
original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Delivery of Warrant
Shares</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant, the Company shall promptly (but in no event than two Trading Days after the Exercise Date),
upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company
(&#147;<I>DTC</I>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program (the &#147;<I>FAST Program</I>&#148;) or if the certificates are
required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#146;s share register in the name of the Holder
or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#147;<I>Person</I>&#148;) permissibly so designated by the Holder to
receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account or the date of delivery of the
certificates evidencing such Warrant Shares, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If by the close of the fifth Trading Day after the Exercise Date, the
Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> or fails to credit the Holder&#146;s balance account with DTC for such
number of Warrant Shares to which the Holder is entitled, and if after such fifth Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<I><FONT STYLE="white-space:nowrap">Buy-In</FONT></I>&#148;), then the Company shall, within two Trading Days after the
Holder&#146;s request and in the Holder&#146;s sole discretion, either (1)&nbsp;pay in cash to the Holder an amount equal to the Holder&#146;s total </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the &#147;<I><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</I>&#148;), at which point
the Company&#146;s obligation to deliver such certificate (and to issue such Warrant Shares) shall terminate or (2)&nbsp;promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Warrant Shares and pay
cash to the Holder in an amount equal to the excess (if any) of Holder&#146;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the <FONT STYLE="white-space:nowrap">Buy-In</FONT> over the
product of (A)&nbsp;the number of shares of Common Stock purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the Closing Sale Price of a share of Common Stock on the Exercise Date. The provisions of this Section&nbsp;5(b)
shall be the only remedy available to the Holder in the event the Company fails to deliver to the Holder the required number of Warrant Shares in the manner required pursuant to Section&nbsp;5(a) and a <FONT STYLE="white-space:nowrap">Buy-In</FONT>
occurs. Irrespective of whether there is a <FONT STYLE="white-space:nowrap">Buy-In,</FONT> no remedy shall be available, notwithstanding the requirements of Section&nbsp;5(a), unless and until the Company fails to deliver to the Holder the required
number of Warrant Shares by the close of the fifth Trading Day after the Exercise Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to
<U>Section</U><U></U><U>&nbsp;5(b)</U>, the Company&#146;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in <U>Section</U><U></U><U>&nbsp;11</U> below) are
absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or
any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and
irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to <U>Section</U><U></U><U>&nbsp;5(b)</U>, nothing herein shall limit the
Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver
certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Charges, Taxes and
Expenses</U>. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding
any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; <I>provided, however</I>, that the Company shall not be required to pay any tax that may be payable in
respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise
as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Replacement of Warrant</U>. If this Warrant is
mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances
shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall
deliver such mutilated Warrant to the Company as a condition precedent to the Company&#146;s obligation to issue the New Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Reservation of
Warrant Shares</U>. The Company covenants that it will at all times while this Warrant is outstanding reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of
enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other
contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of <U>Section</U><U></U><U>&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance
and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable. The Company will take all such action as may be reasonably necessary to assure that such
shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>Certain Adjustments</U>. The number of Warrant Shares issuable upon exercise of this Warrant is subject to adjustment from time to time as set forth in
this <U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is
outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the Original Issue
Date or as amended, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(iii) combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of
Common Stock of the Company, then in each such case the number of Warrant Shares then underlying this Warrant shall be divided by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such
event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the number of Warrant Shares shall
be recomputed accordingly as of the close of business on such record date and thereafter the Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause
(ii)&nbsp;or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Pro Rata Distributions</U>. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution
of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv)&nbsp;cash or any other asset (in each case, &#147;<I>Distributed Property</I>&#148;), then, upon any exercise of this
Warrant that occurs after the record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if
applicable), the Distributed Property that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard
to any limitation on exercise contained therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding
(i)&nbsp;the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity or the stockholders of the Company immediately prior to such merger or consolidation do not own,
directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one transaction or
a series of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock who tender shares representing more than 50% of the voting power of the capital stock of
the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such
transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of
shares of Common Stock covered by <U>Section</U><U></U><U>&nbsp;9(a)</U> above) (in any such case, a &#147;<I>Fundamental Transaction</I>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise
of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of
the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &#147;<I>Alternate Consideration</I>&#148;). The Company shall not effect any Fundamental
Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous &#147;cashless
exercise&#148; of this Warrant pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of
assets of the Company) shall assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The
provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<U>Calculations</U>. All calculations under this <U>Section</U><U></U><U>&nbsp;9</U> shall be made to the nearest share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Notice of
Adjustments</U>. Upon the occurrence of each adjustment pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with
the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the
transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company&#146;s
transfer agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company
(i)&nbsp;declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the
Company or any subsidiary, (ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of
the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such
transaction at least ten (10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; <I>provided, however</I>, that the
failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into
any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section</U><U></U><U>&nbsp;9(c)</U>, other than a Fundamental Transaction under clause (iii)&nbsp;of
<U>Section</U><U></U><U>&nbsp;9(c)</U>, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least thirty (30)&nbsp;days prior to the date such Fundamental Transaction is consummated. Holder agrees to maintain any
information disclosed pursuant to this <U>Section</U><U></U><U>&nbsp;9(f)</U> in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the Company&#146;s securities following receipt
any such information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Payment of Exercise Price</U>. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole
discretion, satisfy its obligation to pay the Exercise Price through a &#147;cashless exercise,&#148; in which event the Company shall issue to the Holder the number of Warrant Shares determined as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals
the number of Warrant Shares to be issued to the Holder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which
this Warrant is then being exercised; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the average of the Closing Sale Prices of the shares of Common Stock (as
reported by Bloomberg Financial Markets) for the five (5)&nbsp;consecutive Trading Days ending on the date immediately preceding the Exercise Date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a &#147;cashless
exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues
to take the position that such treatment is proper at the time of such exercise). Except as set forth in <U>Section</U><U></U><U>&nbsp;12</U> (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be settled in
cash. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>Limitations on Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained in any Section herein, except for <U>Section</U><U></U><U>&nbsp;15</U>, the number of
Warrant Shares that may be acquired by the Holder upon any exercise of this Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to ensure that, following such exercise (or other issuance), the total number of shares of
Common Stock then beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act, does not exceed
9.99% of the total number of then issued and outstanding shares of Common Stock (including for such purpose the shares of Common Stock issuable upon such exercise), it being acknowledged by the Holder that the Company is not representing to such
Holder that such calculation is in compliance with Section&nbsp;13(d) of the Exchange Act and such Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this
<U>Section</U><U></U><U>&nbsp;11(a)</U> applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by such Holder) and of which a portion of this Warrant is exercisable shall be in the sole discretion of
the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#146;s determination of whether this Warrant is exercisable (in relation to other securities owned by such Holder) and of which portion of this Warrant is
exercisable, in each case subject to such aggregate percentage limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination under this
<U>Section</U><U></U><U>&nbsp;11(a)</U> as to any group status shall be determined in accordance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this <U>Section</U><U></U><U>&nbsp;11(a)</U>, in determining the number of
outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> as the case may be, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written request of the Holder, the Company shall, within three (3)&nbsp;Trading Days, confirm orally and in writing to such Holder the number of shares of Common Stock then outstanding. By written notice to the Company, which will not be
effective until the sixty-first (61<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day after such notice is delivered to the Company, the Holder may waive the provisions of this <U>Section</U><U></U><U>&nbsp;11(a)</U> or increase the
beneficial ownership limitation to such percentage of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant as the Holder shall determine, in its
sole discretion, subject to <U>Section</U><U></U><U>&nbsp;11(b)</U>, and the provisions of this <U>Section</U><U></U><U>&nbsp;11(a)</U> shall continue to apply. Upon such a change by a Holder of the beneficial ownership limitation from such 9.99%
limitation to such other percentage limitation, the beneficial ownership limitation may not be further waived or increased by such Holder without first providing the minimum notice required by this <U>Section</U><U></U><U>&nbsp;11(a)</U>.
Notwithstanding the foregoing, at any time following notice of a Fundamental Transaction under <U>Section</U><U></U><U>&nbsp;9(f)(ii)</U> with respect to a <U>Section</U><U></U><U>&nbsp;9(c)(iii)</U> Fundamental Transaction, the Holder may waive
and/or change the beneficial ownership limitation effective immediately upon written notice to the Company and may reinstitute a beneficial ownership limitation at any time thereafter effective immediately upon written notice to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding anything to the contrary contained in any Section herein, except <U>Section</U><U></U><U>&nbsp;15</U> (but including
<U>Section</U><U></U><U>&nbsp;11(a))</U>, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon
giving effect to such exercise, would cause (i)&nbsp;the aggregate number of shares of Common Stock beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the
Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act, to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii)&nbsp;the combined voting power of the
securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to
exceed 19.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this <U>Section</U><U></U><U>&nbsp;11(b)</U>, the aggregate number of shares of Common Stock or voting
securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act shall include the
shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining
unexercised and <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of this Warrant by the Holder and (y)&nbsp;exercise or conversion of the unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or <FONT
STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) This <U>Section</U><U></U><U>&nbsp;11</U>
shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as
contemplated in <U>Section</U><U></U><U>&nbsp;9</U> of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>No Fractional Shares</U>. No fractional Warrant Shares will be issued in
connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash
the fair market value (based on the Closing Sale Price) for any such fractional shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>Notices</U>. Any and all notices or other communications or
deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile or
confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified below prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after
the date of transmission, if such notice or communication is delivered via facsimile or confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified below on a
day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day
delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <U>Warrant Agent</U>. The Company shall initially serve as warrant agent under this Warrant. Upon thirty
(30)&nbsp;days&#146; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new
warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any
further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <U>Automatic Exercise on the Expiration Date</U>. In the event that, upon the Expiration Date, the Closing Sale Price on the Trading Day immediately
preceding the Expiration Date (as determined in accordance with this Warrant) is greater than the Exercise Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant to a
&#147;cashless exercise&#148; to the extent permitted under <U>Section</U><U></U><U>&nbsp;10</U> of this Warrant as to all Warrant Shares for which this Warrant shall not previously have been exercised or converted, without regard to the limitations
on exercise set forth in <U>Section</U><U></U><U>&nbsp;11</U>, and the Company shall promptly deliver a certificate representing such shares issued upon such exercise to the Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a
Stockholder</U>. The Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained
in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action
(whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the
Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities
(upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth
in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase
in par value, (b)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant, and (c)&nbsp;use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in
the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to the restrictions on transfer set forth in this Warrant and the restrictions on transfer set forth
in this Warrant and compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder except to a successor in the event of a Fundamental
Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person
other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take
any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holders of Warrants representing no less than a majority of the Warrant Shares obtainable
upon exercise of the Warrants then outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of
and agreement to all of the terms and conditions contained herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE
CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE
COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH
ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS
NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY
THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE
THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or
affect any of the provisions hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid
or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a
valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Novus Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>SCHEDULE 1 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF EXERCISE NOTICE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be
executed by the Holder to purchase shares of Common Stock under the Warrant] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned is the Holder of Warrant No. ___ (the &#147;<I>Warrant</I>&#148;) issued by Novus Therapeutics,
Inc. (the &#147;<I>Company</I>&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Holder intends that payment of the Exercise Price shall be made as (check one): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;Cashless Exercise&#148; under <U>Section</U><U></U><U>&nbsp;10</U> of the Warrant </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $ in immediately available funds to
the Company in accordance with the terms of the Warrant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in
accordance with the terms of the Warrant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving
effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be
owned under <U>Section</U><U></U><U>&nbsp;11(a)</U> or <U>Section</U><U></U><U>&nbsp;11(b)</U>, as applicable, of the Warrant to which this notice relates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Holder:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>eldn-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 1/7/2021 5:44:53 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:eldn="http://imetrix.edgar-online.com/20201231"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://imetrix.edgar-online.com/20201231"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eldn-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eldn-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>eldn-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 1/7/2021 5:44:53 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>eldn-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 1/7/2021 5:44:53 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eldn-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g27027g0106223143874.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g27027g0106223143874.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X -$# 2(  A$! Q$!_\0
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M;>$GC_>/L*Z?2?\ D#6/_7O'_P"@BO$/&"#7OC[INF7GS6L1C"HW3 4M^I%
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@ )Q2T44 %%%% !Q1Q110 4444 '%'%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g27027g0106224044986.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g27027g0106224044986.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. -(# 2(  A$! Q$!_\0
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M>:@H@BBSS@D;FQZ 5C:1X%\;7?AW3Y;?QS+#%+:QM'$(ON*5&!GV'%>?^+?
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MA_\ 0!6A>VL5[8SVLZ!XIHVC=2."",&LWPK+&?"&CXD4XL8<X8<?(*Q/'WQ
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MT_X*^$;2X$]S!/?RCG-S*6S^%=)_PA6A_P#/O+_W^?\ QH_X0K0_^?>7_O\
M/_C1<+&W:VEO8VR6]K!'#"@PJ1K@"IJY[_A"M#_Y]Y?^_P _^-'_  A6A_\
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;6]S/;S31AI+=R\1R?E)!&?R)HN!/1112 __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d27027d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eldn-20201231.xsd" xlink:type="simple"/>
    <context id="duration_2020-12-31_to_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2020-12-31_to_2020-12-31"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2020-12-31_to_2020-12-31">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-12-31_to_2020-12-31"
      id="Hidden_dei_EntityCentralIndexKey">0001404281</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-12-31_to_2020-12-31">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-12-31_to_2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2020-12-31_to_2020-12-31">Eledon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-12-31_to_2020-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-12-31_to_2020-12-31">001-36620</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2020-12-31_to_2020-12-31">20-1000967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-12-31_to_2020-12-31">19900 MacArthur Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2020-12-31_to_2020-12-31">Suite 550</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-12-31_to_2020-12-31">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2020-12-31_to_2020-12-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-12-31_to_2020-12-31">92612</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2020-12-31_to_2020-12-31">(949)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-12-31_to_2020-12-31">238-8090</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-12-31_to_2020-12-31">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-12-31_to_2020-12-31">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-12-31_to_2020-12-31">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-12-31_to_2020-12-31">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-12-31_to_2020-12-31">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-12-31_to_2020-12-31">ELDN</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-12-31_to_2020-12-31">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140709161110536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001404281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eledon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1000967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19900 MacArthur Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-8090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELDN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M?*A9(]V"K7M)W%[$2KI5 I#G$KI&1XD0G'*ZYK#\ Y%9&4!F74$B!#<(9J_
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M'!+-O0#/EUK;MX8[%Q?_UAC^#U!+ P04    "  :0"=2@ZFE ]0!   R!@
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MAH8/$L];,J=[_!EJ,:@W6]5C6)>E:H\_A?<HN9\;[O\2Q0]02P,$%     @
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ &D G4@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  :0"=2?(96?>\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  :0"=2F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !I
M)U+LG*382@0  .(0   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  :0"=2@ZFE ]0!   R!@  #0
M        @ &.#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !I )U*7BKL<
MP    !,"   +              "  8T.  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( !I )U(<.&7J/P$  #P"   /              "  78/  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  :0"=2)!Z;HJT   #X 0  &@
M    @ 'B$   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  :0"=299!YDAD!  #/ P  $P              @ ''$0  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"   1$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d27027d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d27027d8k.htm">d27027d8k.htm</File>
    <File>d27027dex101.htm</File>
    <File>d27027dex102.htm</File>
    <File>eldn-20201231.xsd</File>
    <File>eldn-20201231_lab.xml</File>
    <File>eldn-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d27027d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d27027d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eldn-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eldn-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "eldn-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "eldn",
   "nsuri": "http://imetrix.edgar-online.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d27027d8k.htm",
      "contextRef": "duration_2020-12-31_to_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d27027d8k.htm",
      "contextRef": "duration_2020-12-31_to_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://imetrix.edgar-online.com//20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-21-003750-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-003750-xbrl.zip
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M]]^!P5\(2C::PR0^RK@E/0:S#FZ)^T0G"@T[-([?.DA=&(AHA6S\4-<_I\F
M_'%N_ZBB/V&@^5A]$KK;-XZAT]E-LO=WG:M6I]2\N[FYO.^V&LG%7WN3S#07
M[I(1?0E8TML_ZYR3;+&6I\/L.$&QH3> $))@8P(VBH $L+32U7;.W<CVO:\M
ML%4N^0*AK!CUKUYF:ZE+7:;325J?0UA1,NMH>>I^;+X+=K3$]&MVP&8#]G$;
M=+NEX,XCR7MJ\6S%+ZL5R:H7;L@!FE;,A+",TV:RN,*=>?JN",89C'AT;'XK
M'D-%'L"[H;YN(FZ@2+2J:N<%+#<N1XF=I@/)HHW';"==6#R ]3\R]CRA2SJ.
MUI+W7 3,'GI@4 83\ANZ_^0:IJA(;LKWT.^R<M)NKR*)?>^(]*X;D9(B^=AM
MD_>_79/N_6_X[ 9?!\_RC64QRUA=!RA#P!B3*N4;%C72!$]!Z%7U@RO 12 _
M,^H&0YM*!IXK(BH9Q3VT+P:1QZA'C+VMZ*9(,NRL8:686T^C&#2SB,Y62R?-
M63U7Z4BKM5KQZ.B(* !5I!M8+0,@G5AC1\&<BH*Y-(I+PSK\V@8V,(O"- *<
M#@>=C:.B953+]9-,KRF'3>%I:X.V_5Y_-41K+C:R>$@S1$E/9;+":;->0G/;
M'L%5 BU0D8AE:IR5[[8J]SN5&I#S&E>,AZV1.P_&%;JZ"(R98I77Y;7(7HS6
M%566('9VJ-L.L)@TE/4XIX,Y-.I%TSR>AWV*6 U43"6#/V '6#[T7;0Q#$:V
MU,>EQTE"VJ=H$ J% 8(!)L 9AT;H ,0[B%^LW8 5&A *_OP(/'"= "EM\,@Q
M)])FBX2F]J<##]FYF%5?/75 D+!)G@#\$%2K$$AP*D48I-&,CAN69L3$X7,1
M@VXZB@*;O'7(DD^M#P3FDKD<OQ6&*AH%1FSDZ][Z4HSR_6-P29.(/G<8A0'-
M0?W=XNC^]>5^G>:RY?!>S%D;C [-6K%J'!6/S%H&<#FPP23HJ$XG3<*,K3+6
MLS.<J5N,U1]7!3MCT[6IBU:=ZC(6#F@?EU<)4:9F U6Q+ZD6/VA 5&M/Z,:P
M:2"0*X<I6W(_FVZXP'YJ 6 LKB-L%C M5*[(YQ"3OC/O'.,K$Y*!6PI1_O1S
M66@[=+9BZ+J:^Q5]967>Y^ M:O7 967(>SR(FH*NHX\+)(Q,7VF""MF^"9A8
MQKTY.6=D=O*ER0UO<=OF<5N];)A_E[CM.MUMTB]?Q*H$@&U%6-YMQ+:5%3AP
MWJ5<-%;HAO7220B[T9T-LA!P@R?.1(@OG$CDR=TF.0-+TA6BPGHMES,P[?!%
M3]06J4><:V*4S6W/8):>Q"P\:*$D^IRC8QT;UK'#QJ9AEH?!"--B5CCKCK;2
MRW8(P'JCCE!82@=+(_W4#\NYX;C=KA^CR0=4TZ6'FQF9SHLT><4!2Q:((E,,
M"R*"'$R6]<J?+)B?CX6)'BD2K%='@A4A846\]P:$UP9" H?:BZ*A*> IN8?1
MPA2!$XQ.[R,C5S2@1+_H?(#S[3AQQ,2C&*:M/[U,\-O+Q(F_I?4N:T[391$O
MIT<(VLK^K<\1]OK::[?]X?;RX==.Z]4CF>Q'[J(SQ,\A!!^1F[79*7,46W;R
MAX].Z$Z(34.E30A7\7?"L)L>^/PP>"@04;S38T/J]M%484/:]XL)T/:$&"?J
MYF"NAD+"P)Q5D<C7ZVTM]*]FDJE3]V@;CVMEEN9V+:YHZ'#WK-5>^R-&V^;6
M?!WTTX6U^ORTU0V,R>H/P?DK_?I-? C4[55.A"Z?]R)>BG;/H,0/,C9(_&W-
M"!'Q!S9?#GC/WS.8L;HOQ^+[2>-5QK^!\JS)Y]A2NRJJ N[?(W=*ERX;@\LN
M&6F6R0<IU*NGH'X==F]K>LQ.?$'T+)V]_<_<5Z#87P&+.D/Z!0'4''+6!R<\
M^?+)G?[RB=PTP#NKZ/]BYDS_!S07_P=02P,$%     @ &D G4G6*9)B:$0
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M;T G]L#E*?YBP*VP(;"^Q<KES<;MEC.PRN+(.X*&=>?APUD!>B]F\3 9)[A
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MX;-GS^P;F$5\.]*\G3'>KF[W?9.8%4V^(RK;W P?/7GZ?5/95<9H4]D]:[M
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MMG.;L1K+R;^V.<)X*3!CLLN5$U!=.):@;^$*6GU&ULKH"R<&H,4H<2X.H2M
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ME&Y[:+(\_.[0J&'L>X7[,%0N2*UXN3RP9-\/0%8.G<4,.[+;6#Q<^;.HP?[
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M?FN6^-KOH7U$R-Q/GI"O9CXY(;U-.47]SFLA!IT2TB,EOY^N!$4QDRZDPR_
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M7*HM_14P^2Z:?1&*VO,_4$L#!!0    ( !I )U(8(#I*U 0  -XL   5
M96QD;BTR,#(P,3(S,5]P<F4N>&ULU9I=<^(V%(;O=V;_@^J]:6=JC"%I&B9D
MAY)DARE)&,*VG=[L"/L FLH2(XD _[Y'!NWR8;*0[7:L7 0CZSUZ=1XA6[*O
MWB\R3IY!:29%,X@KU8" 2&3*Q+@9S'1(=<)80+2A(J5<"F@&2]#!^^NW;ZY^
M"$-R<]=Y("&9&#/5C2B:S^>5=,2$EGQF,*2N)#*+2!BZ^NW!1_+'JKD&Z0,'
MJH'4JK5J>$%^FS&>-NR7.(ZKE7A3IH#:>"2E!AHDCBXBK!>3\\;96>.\3GKW
MY)9J TJ0 <M@4RFG2\7&$T-^3'XBN>A&"@&<PY+<,4%%PB@G3\[PSZ0CD@II
M<4[Z5J;1I0;U#&EE'94S\4_#_AM:[^3M&X)_F$:A\])F8).QSL5BJ'A%JC&Z
MK=8C)PHV-8L]T;R>2^++R\LH/[M=7[.BVMA '/UUWWU*)I#1$!$@LF2G*723
MFL_J37/GT>JDJZ]90^>1NC+),W]$M\C!&O9;Z*J%MBB,:V$]KBQT&ES;)E=9
M59)#'T;$?G[L=SZWB4B-8HL*I&.J0BFP,N0C*\I'2ZT>1X8NI)#9,K+:Z$8F
MLPR$<9\MD=X*P\RR(T9297F/ I(GMS%1,&H&P%,1NFC6U[L^!OIT2B"SG.+/
M0[-LRB$@T4:_I@K'D#!Y[2X6; E@84"DD+HPM@/?N>?7*\KKH2R3K4RXWW*.
M4$-2&<OG* 6&+<:7]B"T!V$U7@-\AT6?VA(GD=90&T43LYT0;D>05*Z0TR'P
M9E @BOY[6T^0S!1V_G:13*@8PP/-X%AWQ=IMDYM@6RK9BDQ5XJ+BX1;5_5_(
MND8TI0KCA<D$IT*G'BF9%29LW9I\R:]4*:AF4*M5<(((R%0Q:2MA24!F&BW)
MJ35/N3T'(U *TNXJ"0?-YDYQLM60U_PNY%HX>%,[@.\X'1^+;$=47E8[1AVD
MNF>05C-+&_NA*._@)+;X'9;'PCH@+B^T X8=O#//X+DKQ "3>2RS;4UY46W[
M=(1^\910#] Q7L;3&[S[/175CKC\S'8,.W@7GL%;S19]&#/;76%.N?4HUI87
M7;%?1^Y7+\GA,E"JJ51Y@I\PS]"6,YSZEVV9G@CR*Z'*SO4K]AWF2R\QWS$.
M#[-L".HTIINZL@/<]+JF5:]Z26M %YT4D\%&;+4M\1IT!X.4G>-!XPYJ["74
M5IIBJO7ZH\L$Q*<!+0Q0=IB%IAU(WU;KA[I4^U:0-1]!UKZ ]'-%O^Y+&P\?
MU4#.Q:LP;LH]@;AIV2'T;5V_U:'\=NU1]91\9O9QP&LX[L7P!.:>;T?TW&>B
M/:D-Y7^SZ>GKD.((GM#<<>U8^K:G8V>8E@)Z"KUM37EY;?MTA'S;N+%//'EO
M(L6)Z\)]77E)[7MUM'S;K/D371H0;9EE,[%>%NECD1T0EY?; <,.GF];,$^2
MLX09)L;W>*E6S!H\\N%L@;*\V(K<KIF=^;81TU-@AQ_@'57^A,6^NZ >1Z/C
M)\J7(I27X4NN'4O?]E]V^M31>@;JVXD6Q/&&:X%W1]>W31GW0DA<&PZ8X2>_
M^/)%5UYZ^UX=+=]V7@:*VK<NGY;94!Y]&=P1E9?3CE$'R<^]E=L,U!A[\T')
MN9G@[#&EXL377@Z$*"_ %VT[G/_#QLI5M)>:+A;8%W-79^P_^YHIEOP+4$L!
M A0#%     @ &D G4JK %'YR$   *&H   T              ( !     &0R
M-S R-V0X:RYH=&U02P$"% ,4    "  :0"=2=8IDF)H1   /9P  $
M        @ &=$   9#(W,#(W9&5X,3 Q+FAT;5!+ 0(4 Q0    ( !I )U)(
MA0XZN$0  ,YC 0 0              "  64B  !D,C<P,C=D97@Q,#(N:'1M
M4$L! A0#%     @ &D G4L\K8D%I P  /0P  !$              ( !2V<
M &5L9&XM,C R,#$R,S$N>'-D4$L! A0#%     @ &D G4E0XW1F'!@  2$<
M !4              ( !XVH  &5L9&XM,C R,#$R,S%?;&%B+GAM;%!+ 0(4
M Q0    ( !I )U(8(#I*U 0  -XL   5              "  9UQ  !E;&1N
G+3(P,C Q,C,Q7W!R92YX;6Q02P4&      8 !@!\ 0  I'8

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
